Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines
Vasograin Plus represents a major advancement in the treatment of migraine
Vasograin Plus represents a major advancement in the treatment of migraine
cSCC is one of the most common cancers in the U.S. and globally
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The submission is supported by results from the Phase 3b APEX study
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Subscribe To Our Newsletter & Stay Updated